Program
miricorilant
Also written as “Miricorilant”, “Miricorlilant” and “Miricorilant (Cohort A)”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Weight Gain, led by Corcept Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Corcept Therapeutics | 140 open or running | phase 2since Jan 14, 2019 | Sep 27, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2017First study: phase 1 study in HealthyFirst studyNCT03315338 · 143 enrolled · United Kingdom
- Jan 14, 20192 phase 2 studiesNCT03823703, NCT03818256
- Mar 14, 20192 phase 1 studiesNCT03878264, NCT03877562
- Aug 6, 2020Phase 2 study in ObesityNCT04524403 · 150 enrolled · United States
- Dec 14, 2020Phase 1 study in HealthyNCT04672499 · 36 enrolled · United Kingdom
- Oct 12, 2021Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05117489 · 70 enrolled · United States
- Sep 21, 2022Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05553470 · 19 enrolled · United States
- Jan 25, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT05712265 · 26 enrolled · United States
- Oct 23, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06108219 · 175 enrolled · United States, India, Puerto Rico
- Apr 21, 2025Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06947304 · 9 enrolled · United States
- Nov 7, 2025Phase 1 study in HealthyNCT07240116 · 18 enrolled · United States
- Apr 14, 2026Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07553663 · 14 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07553663Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Sep 22, 2026 | 14 |
| NCT07240116Healthy · United States | 1 | Completed | Mar 3, 2026 | 18 |
| NCT06947304Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Aug 13, 2026 | 9 |
| NCT06108219Non-alcoholic Fatty Liver Disease · United States, India, Puerto Rico | 2 | Completed | Feb 13, 2026 | 175 |
| NCT05712265Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Feb 23, 2023 | 26 |
| NCT05553470Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Sep 13, 2024 | 19 |
| NCT05117489Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Jan 29, 2024 | 70 |
| NCT04672499Healthy · United Kingdom | 1 | Completed | Sep 7, 2020 | 36 |
| NCT04524403Obesity · United States | 2 | Completed | Jul 29, 2022 | 150 |
| NCT03878264Healthy · United Kingdom | 1 | Completed | Mar 24, 2019 | 12 |
| NCT03877562Antipsychotic-induced Weight Gain · United Kingdom | 1 | Completed | Mar 13, 2020 | 96 |
| NCT03818256Obesity · United States | 2 | Completed | Jun 17, 2022 | 71 |
| NCT03823703Non-alcoholic Fatty Liver Disease · United States | 2 | Terminated | Apr 5, 2021 | 12 |
| NCT03315338Healthy · United Kingdom | 1 | Completed | Feb 22, 2019 | 143 |
How it is read
Names in the registry
- “Miricorilant”, 6 entries
- “Miricorlilant”, 2 entries
- “Miricorilant (Cohort A)”, 1 entry
- “Miricorilant (Cohort B)”, 1 entry
- “Miricorilant Treatment A”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 7 studies
- Obesity, 2 studies
- Weight Gain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.